P
Pavel Mozgunov
Researcher at Lancaster University
Publications - 48
Citations - 430
Pavel Mozgunov is an academic researcher from Lancaster University. The author has contributed to research in topics: Medicine & Computer science. The author has an hindex of 8, co-authored 37 publications receiving 186 citations. Previous affiliations of Pavel Mozgunov include Fylde College, Lancaster University & National Research University – Higher School of Economics.
Papers
More filters
Journal ArticleDOI
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Saye Khoo,Richard Fitzgerald,Tom Fletcher,Tom Fletcher,Sean Ewings,Thomas Jaki,Thomas Jaki,Rebecca Lyon,Nichola Downs,Lauren Walker,Olana Tansley-Hancock,William Greenhalf,Christie Woods,Helen Reynolds,Ellice Marwood,Pavel Mozgunov,Emily R. Adams,Katie Bullock,Wayne Holman,Marcin D Bula,Jennifer L Gibney,Geoffrey Saunders,Andrea Corkhill,Colin Hale,Kerensa Thorne,Justin Chiong,Susannah Condie,Henry Pertinez,Wendy Painter,Emma Wrixon,Lucy Johnson,Sara Yeats,Kim Mallard,Mike Radford,Keira Fines,Victoria Shaw,Andrew Owen,David G. Lalloo,Michael Jacobs,Gareth Griffiths +39 more
TL;DR: In this article, the authors evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection in a Bayesian adaptive Phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility.
Journal ArticleDOI
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
Thomas Burnett,Pavel Mozgunov,Philip Pallmann,Sofia S. Villar,Graham M. Wheeler,Thomas Jaki,Thomas Jaki +6 more
TL;DR: The main features of adaptive designs and commonly used terminology are introduced, highlighting their utility and pitfalls, and their use is illustrated through case studies of adaptive trials ranging from early-phase dose escalation to confirmatory phase III studies.
Journal ArticleDOI
Efficient adaptive designs for clinical trials of interventions for COVID-19
Nigel Stallard,Lisa V. Hampson,Norbert Benda,Werner Brannath,Thomas Burnett,Tim Friede,Peter K. Kimani,Franz Koenig,Johannes Krisam,Pavel Mozgunov,Martin Posch,James Wason,James Wason,Gernot Wassmer,John Whitehead,S. Faye Williamson,Sarah Zohar,Thomas Jaki,Thomas Jaki +18 more
TL;DR: In this article, the authors describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting, illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.
Posted ContentDOI
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
Save H. Khoo,Rose Mary Fitzgerald,Gillian Saunders,C. Middleton,Sara Ahmed,C. Edwards,D. Hasdjiyiannaskis,Lauren Walker,Rebecca Lyon,V Shaw,Pavel Mozgunov,J Periselneris,Christie Woods,Katie Bullock,C. Hale,Helen Reynolds,Nichola Downs,Sean Ewings,A. Buadi,D. Cameron,Taylor Edwards,Ellen Knox,I'ah Donovan-Banfield,William Greenhalf,Justin Chiong,L. Lavelle-Langham,Michael Jacobs,Wendy Painter,Wayne Holman,D. Lalloo,Michelle Tetlow,Julian A. Hiscox,Thomas Jaki,Tracey Fletcher,Gareth Griffiths,Agile CST-2 Study Group +35 more
TL;DR:
Journal ArticleDOI
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye Khoo,Richard J. FitzGerald,Geoff Saunders,C. Middleton,Shazaad Ahmad,C. Edwards,D. Hadjiyiannakis,Lauren Walker,Rebecca Lyon,Victoria Shaw,Pavel Mozgunov,Jimstan Periselneris,Christie Woods,Katie Bullock,C. Hale,Helen Reynolds,Nichola Downs,Sean Ewings,A. Buadi,D. William Cameron,Thomas E. Edwards,Emma Knox,I'ah Donovan-Banfield,William Greenhalf,Justin Chiong,L. Lavelle-Langham,Michael Jacobs,Josh Northey,Wendy Painter,Wayne Holman,David G. Lalloo,Michelle Tetlow,Julian A. Hiscox,Thomas Jaki,Thomas M. Fletcher,Gareth Griffiths,Nicholas I. Paton,Frederick G. Hayden,Janet Darbyshire,Amy Lucas,U. Lorch,Andrew N. Freedman,Richard J. Knight,Stevan Julious,Rachel L Byrne,A. C. Cubas Atienzar,Jayne Jones,C. K. Williams,Anna Song,Joanna Dixon,Anita Alexandersson,Parys Hatchard,Emma Tilt,and Jeremy J. Titman,Alejandra Doce Carracedo,Vatsi Chandran Gorner,Andrea Jane Davies,Louis Woodhouse,N. A. Carlucci,Emmanuel C. Okenyi,Marcin D Bula,Kate Dodd,Jennifer Gibney,L.C. Dry,Zalina Rashid Gardner,Amin Sammour,Christine P. Cole,Tim Rowland,Maria Tsakiroglu,Vincent Yip,Rostam Osanlou,Annabel Murray Stewart,Ben Parker,Tolga I Turgut,Afshan Ashfaque Ahmed,Kay Starkey,S. Raghul Subin,Jennifer Stockdale,Lisa Herring,Jonathon P. Baker,A Oliver,Mihaela Pacurar,Daniel R Owens,Alistair Munro,Gavin Babbage,Saul N. Faust,Matthew J. Harvey,Dan W. Pratt,Deepak Nagra,Aashish Vyas +89 more
TL;DR: Molnupiravir was found to be well tolerated in vaccinated and unvaccinated individuals with COVID-19 and, although predefined threshold not reached, this is conclusive evidence that antiviral drug molnupIRavir has a broad evidence of antiviral activity in vaccinated individuals, although some evidence is not reached.